70 likes | 192 Views
2008 Update on Technology Transfer at the University of Colorado. David N. Allen Associate VP for Technology Transfer University of Colorado 303 735 1688 david.allen@cu.edu. FY 2007-08 Review.
E N D
2008 Update on Technology Transfer at the University of Colorado David N. Allen Associate VP for Technology Transfer University of Colorado 303 735 1688 david.allen@cu.edu
FY 2007-08 Review • CU technology transfer continues to advance and provide benefits to the University, the Colorado economy and society. • Highlights of the year – • Growth in exclusive license and option activity • Eleven new companies created based on CU intellectual property and continued success of companies in the portfolio • Increasing leverage of State bioscience funding program • Decrease in non-exclusive licenses • First year of decreased revenues
CU Technology Transfer Today Fiscal Year 03-4 04-5 05-6 06-7 07-08 Invention disclosures 147 177 198 254 237 Patent apps filed 100 139 125 177 188 Options and licenses 47 59 57 75 58 Exclusive option/licenses 19 22 36 38 45 Revenue in $MM* 5.8 21.7 20.6 24.0 6.1 Start-up companies 9 9 10 10 11 * does not include revenue derived from legal settlements which in FY2003-4 amounted to $28.1M, in FY2004-5 $6.7M, in FY 2005-6 $.7M and $.5M in 2006-7
Companies Created Based on CU IP • Eleven companies (start-ups) created from CU IP last FY • 83 start-ups in the past 15 years; all but twelve remain operational • 67 start-ups have Colorado operations • Fourteen start-ups have received CU TTO Proof-of-Concept investments • Fifteen IPOs and acquisition events have occurred within the start-up portfolio
The Maturing Intellectual Property and Licensing Portfolio • 269 active patents • 267 active patent applications • 113 active exclusive licenses and 20 options to exclusive licenses • 190 active nonexclusive licenses • 44 therapeutics, 32 diagnostic tests and 37 medical devices in preclinical development
Social, Clinical and Economic Impacts of CU Technology Transfer • Three FDA approved drugs being sold • Three drugs in Phase III clinical trials • 11 drugs in Phase II clinical trials • Six drugs in Phase I clinical trials • Companies created from CU IP secured $116M in investment capital in 2006 • 30 total products being sold based on CU IP
Continuing the Momentum and Facing New Challenges and Opportunities • Reliable flow of IP and license transactions based on active research investigators, consistent IP practices, staff development, outreach, and leveraging • Challenges… • Retaining CU’s team of quality technology transfer professionals • Two licensing professionals promoted to Senior Licensing positions • Major patent expiration and end of monetization agreement resulted in the first of three years of projected revenue downturn • New License Income in FY 07-08 = $.9M, higher than projected • New opportunities… • State of Colorado Bioscience Development grant for five years • Colorado Renewable Energy initiatives